Abstract
In the article “Lamotrigine extended-release as adjunctive therapy for partial seizures” by D.K. Naritoku et al. ( Neurology ® 2007;69:1610–1618), as a result of changes to the database from audits conducted across all participating study sites, some of the data reported in the manuscript have changed slightly. These audits were conducted by the study sponsor, GlaxoSmithKline, in preparation for response to the FDA approvable letter for the Lamictal XR New Drug Application. The outcome of the audits did not change the overall conclusions of the …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
